With 16 cancer drugs currently on the FDA’s drug shortage list, Jason Westin, MD, the director of Houston-based MD Anderson Cancer Center’s Lymphoma Clinical Research Program, section chief for Aggressive Lymphoma, told the Senate Finance Committee Dec. 5 that “providers shouldn’t have to make impossible choices about patient care.”
Read the full post on Becker's Hospital Review - Healthcare News
